BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Proteros biostructures GmbH Collaboration with UCB Group (UCBJF.PK)


3/6/2009 8:02:06 AM

MARTINSRIED, Germany--(BUSINESS WIRE)--Proteros biostructures GmbH (Martinsried, Germany) today announced it has signed a research services agreement with UCB (Brussels, Belgium) where Proteros will support the structure-based discovery of small molecule drugs.

In the initial stage of the programme, Proteros will leverage its expertise in gene-to-structure projects and its proprietary technologies to solve the three dimensional structure of an undisclosed target together with its related proteins.

After the establishment of these crystallography systems, Proteros will screen fragments and compounds supplied by UCB with the objective of solving high resolution X-ray structures of the fragments and compounds to confirm the binding modes to the proteins, and therefore facilitating the medicinal chemistry and optimisation of small molecules.

Dr. Torsten Neuefeind, Proteros’ Chief Executive Officer, commented: “We are very pleased to extend our successful relationship which we first entered in 2007, and now to be considered a key partner for UCB in this important project with UCB New Medicines™.”

The financial terms of the fixed research fees and milestones are not disclosed.

About Proteros biostructures GmbH:

Proteros biostructures is a privately held company, which provides services and unique technologies to support drug discovery within life sciences. The company accelerates and improves protein structure analysis and structure-based drug discovery by its expertise, industrialised process and unique technologies for crystallography and fragment screening. Proteros complements its clients’ internal capabilities with its external expertise and access to flexible resources. Proteros currently provides services to over sixty pharmaceutical and biotechnology companies in North America, Europe and Japan. More information about Proteros can be found on the company’s website at www.proteros.com.

Contact:

Proteros biostructures GmbH Dr. Peter Reinemer, Executive VP Scientific Marketing Phone: +49-89-7007-61-0 Email: business@proteros.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES